 A few months ago, gene sequencing juggernaut Illumina Inc. ILMN , Financial seemed like it was well on its way to becoming a fallen giant. Amid flagging growth, the company had jumped the gun by re-acquiring Grail, a cancer testing startup that it had previously spun off in 2016, before securing regulatory approval in the EU. 